Closed · RFA-FD-17-001 · CFDA 93.103 · Discretionary

Expanded Access to Investigational Therapies (R01)

Federal grant opportunity posted by Food and Drug Administration, cataloged on Grants.gov.

up to $300K
Award range
Closed
Status
January 13, 2017
Close date
1
Expected awards

The verdict

Expanded Access to Investigational Therapies (R01) is a closed discretionary listing from Food and Drug Administration that offered Up to $300,000 across 1 expected award. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 481 other opportunities from Food and Drug Administration.

up to $300K
award range
Closed
application status
1
expected award
93.103
CFDA program

Archived opportunity record

Expanded Access to Investigational Therapies is closed (last close January 13, 2017). The parent program page for CFDA 93.103 is the reliable place to catch re-announcements. Food and Drug Administration still indexes 481 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed January 13, 2017

Posted Oct 24 Closes Jan 13

Est. Total Funding

$300,000

Expected Awards

1

Instrument

Grant

Description

The goal of this grant is to develop a framework to guide the improvement of the U.S. system for expanded access to investigational therapies, taking into consideration ethical, scientific, regulatory, financial, and infrastructural issues. Research to improve our understanding of the barriers to expanded access, such as regional and economic bias, will benefit the U.S. public at large by providing researchers and policymakers across the United States a better understanding of the issues implicating expanding access to investigational therapies. • Research and examine the landscape and develop a framework to guide the improvement of the U.S. system for expanded access to investigational therapies, taking into consideration ethical, scientific, regulatory, financial, and infrastructural issues. Articulate guiding principles and an ethical framework for expanded access to investigational therapies. • Research and address scientific considerations and implications for medical product clinical development programs when the investigational product is available through an expanded access program. • Research and address regulatory considerations and the role of FDA, including providing guidance for the collection and evaluation of both safety and efficacy data relating to investigational products provided through expanded access programs. • Research and address business and financial considerations relating to offering investigational products through expanded access programs, including consideration of: o Financial considerations for both small and large companies, and business models for manufacturing and furnishing the products outside of the context of a development program; o Liability and related legal considerations relating to providing unapproved therapies to patients outside of the context of a research protocol; and o Implications for continued access after approval if the product is not affordable to a patient who had been granted expanded access. o Identify characteristics of the optimal structure and governance of a system for expanded access, including making recommendations relating to: o Guidance to and structure of ethics review committees; o Systems for reporting and accountability of companies providing investigational products through an expanded access mechanism; and o Improvement of information sharing among the multiple decision making parties (provider, sponsor, and FDA) to facilitate patient access to investigational therapies through the most appropriate means (e.g., clinical trials, expanded access programs, individual access requests).

Catch-all / unrestricted eligibility mark · RFA-FD-17-001

Grants.gov marks Expanded Access to Investigational Therapies with a catch-all / unrestricted eligibility code (Others (see official listing text)). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity codes span Agriculture · Consumer Protection · Food and Nutrition (AG;CP;FN). 119 other Food and Drug Administration listings share this eligibility-code string (25% of 482).

Code 25
Others (see official listing text)

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

Shashi Malhotra Grants Management Specialist Phone 240-402-7592

What to do next

Expanded Access to Investigational Therapies is closed; use the parent program and agency catalog for the next funding cycle.

  • Parent CFDA 93.103 may publish future NOFOs under the same assistance listing. Open program
  • Food and Drug Administration Research indexes 42 Grants.gov listings in this extract. Program profile
  • Food and Drug Administration lists 481 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants